WebSep 19, 2024 · "We are pleased to announce the positive results from the full set of subjects from the CANAL trial, which are consistent with the previously announced interim analysis and further demonstrated that Haduvio has the potential to reduce IPF patients' cough," said Jennifer Good, President and CEO of Trevi Therapeutics. "We analyzed the change of ... WebApr 11, 2024 · Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn. Investor Contact Katie McManus Trevi Therapeutics, Inc. 203-304-2499 …
Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q3 2024 …
WebMar 16, 2024 · "Following the very encouraging results from our Phase 2 CANAL trial in IPF chronic cough, we have entered a transformational period in the development of Haduvio for the treatment of serious chronic cough conditions," said Jennifer Good, President and CEO of Trevi Therapeutics."With a strong balance sheet and cash runway expected into 2026, … WebNov 14, 2024 · Trevi Therapeutics, Inc. ( NASDAQ: TRVI) Q3 2024 Earnings Conference Call November 10, 2024 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference... dosis uni jena medizin
Trevi Therapeutics to Participate in the 22nd Annual Needham …
WebApr 11, 2024 · Jennifer Good, President and Chief Executive Officer, along with Dr. Bill Forbes, Chief Development Officer, will participate in a fireside chat on Tuesday, April 12, … WebApr 14, 2024 · New Pharmaceutical Company Trevi Therapeutics demonstrates ... Best Stocks WebNov 11, 2024 · Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Conference Call November 10, 2024 4:30 PM ET. Company Participants. Jennifer Good - President and … dosis paracetamol anak injeksi